Tsubota Laboratory Incorporated (4890) AI Stock Analysis

• Market Cap: ¥10.06B
• Dividend Yield: N/A
• Average Volume (3M): 40.38K
• Price to Earnings (P/E): 49.4
• Beta (1Y): 0.72
• Revenue Growth: 101.49%
• EPS Growth: N/A
• Country: JP
• Employees: 7
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 4.74
• Shares Outstanding: 25,654,300
• 10 Day Avg. Volume: 41,300
• 30 Day Avg. Volume: 40,376
• PEG Ratio: 0.11
• Price to Book (P/B): 7.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥422.00
• Price Target Upside: 6.30% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 71 Outperform
• Price Target: ¥439.00 ▲(10.58%Upside)

Tsubota Laboratory's strong financial performance underpins its stock score, supported by robust revenue growth and profitability. However, challenges in cash flow and a high P/E ratio temper enthusiasm. Technical indicators suggest short-term caution.

Tsubota Laboratory Incorporated Business Overview & Revenue Model

Company Description

Tsubota Laboratory Incorporated (4890) is a company specializing in the development and commercialization of innovative solutions primarily focused on the healthcare and life sciences sectors. The company is engaged in the research and production of advanced therapeutic and diagnostic products designed to address unmet medical needs and improve patient outcomes. Tsubota Laboratory leverages cutting-edge technology and scientific research to deliver high-quality products and services that contribute to the advancement of healthcare.

How the Company Makes Money

Tsubota Laboratory Incorporated generates revenue through the sales of its therapeutic and diagnostic products, which are developed based on extensive research and innovation in the healthcare field. The company may also earn income from licensing agreements, collaborations, and partnerships with other healthcare and pharmaceutical firms, allowing it to expand the reach and application of its technologies. Additionally, Tsubota Laboratory might receive funding or grants for research and development projects from both private and public sources, contributing to its financial resources.

Tsubota Laboratory Incorporated Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	1.29B	673.53M	954.69M	640.92M	687.50M	441.00M
Gross Profit	1.21B	20.53M	719.14M	557.02M	606.76M	277.00M
EBITDA	426.22M	-602.60M	184.19M	241.07M	271.61M	0.00
Net Income	397.92M	-641.32M	90.18M	153.32M	201.61M	3.00M
Balance Sheet
Total Assets	2.28B	2.30B	2.67B	1.62B	1.08B	530.00M
Cash, Cash Equivalents and Short-Term Investments	1.83B	1.88B	2.16B	1.17B	610.77M	380.00M
Total Debt	131.63M	116.90M	139.34M	223.82M	242.35M	60.00M
Total Liabilities	817.11M	927.93M	722.59M	873.44M	487.55M	-1.00K
Stockholders Equity	1.46B	1.37B	1.95B	744.35M	591.03M	330.00M
Cash Flow
Free Cash Flow	0.00	-313.35M	-20.27M	582.69M	-8.63M	258.50M
Operating Cash Flow	0.00	-301.35M	28.49M	654.91M	36.72M	262.84M
Investing Cash Flow	0.00	-12.00M	-54.03M	-72.23M	-43.60M	-4.41M
Financing Cash Flow	0.00	35.74M	1.01B	-18.53M	236.97M	18.58M

Tsubota Laboratory Incorporated Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 397.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Neutral. The current price of 397 is above the 20-day moving average (MA) of 395.65, above the 50-day MA of 395.94, and below the 200-day MA of 410.94, indicating a bearish trend. The MACD of -1.80 indicates Positive momentum. The RSI at 48.55 is Neutral, neither overbought nor oversold. The STOCH value of 7.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4890.

Tsubota Laboratory Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3417	80 Outperform	¥14.98B	5.61		2.39%	4.42%	20.59%
4350	73 Outperform	¥15.18B	11.65		2.38%	6.09%	-30.07%
4890	71 Outperform	¥10.06B	49.42		―	101.49%	―
3544	65 Neutral	¥11.47B	14.98		1.20%	4.87%	63.01%
2796	62 Neutral	¥5.82B	―		2.82%	16.60%	-19.16%
8095	60 Neutral	¥19.04B	8.67		3.81%	11.92%	-237.35%
Sector *	52 Neutral	$7.49B	0.22	-61.87%	2.28%	16.62%	1.08%

Tsubota Laboratory Incorporated Corporate Events

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

Tsubota Laboratory, Inc. reported significant financial improvement for the fiscal year ended March 31, 2025, with net sales doubling and a return to profitability. This positive shift in financial performance underscores the company’s strengthened position in the industry, although the forecast for the next fiscal year indicates a slight decline in profits, suggesting potential challenges ahead.